<\/b><\/p>\n
<\/b><\/p>\n
FRIDAY, Oct. 2, 2020 (HealthDay News) — Plasma caffeine concentration is lower in individuals with Parkinson disease (PD), especially LRRK2<\/i> mutation carriers, according to a study published online Sept. 30 in Neurology<\/i>.<\/p>\n
Grace F. Crotty, M.D., from Massachusetts General Hospital in Boston, and colleagues performed metabolomics profiling in individuals with PD and unaffected controls (UC) with and without the LRRK2<\/i> mutation. Plasma was included from 368 PD and UC individuals comprising 118 LRRK2<\/i>+\/PD+, 115 LRRK2<\/i>+\/UC, 70 LRRK2<\/i>\u2212\/PD+, and 65 LRRK2<\/i>\u2212\/UC. Differences were assessed for 282 analytes quantified in plasma and cerebrospinal fluid (CSF).<\/p>\n
The researchers found that PD versus UC individuals had lower plasma caffeine concentration, more so among LRRK2<\/i>+ carriers than LRRK2<\/i>\u2212 individuals (by 76 versus 31 percent), with a significant interaction between LRRK2<\/i> and PD status. For caffeine metabolites and a non-xanthine marker of coffee consumption, similar results were found in plasma and in the subset of corresponding CSF samples. Compared with LRRK2<\/i>+\/UC, dietary caffeine was also lower in LRRK2<\/i>+\/PD+, with a significant interaction effect with the LRRK2<\/i>+ mutation.<\/p>\n
“These results are promising and encourage future research exploring caffeine and caffeine-related therapies to lessen the chance that people with this gene develop PD,” Crotty said in a statement.<\/p>\n
Several authors disclosed financial ties to Denali Therapeutics.<\/p>\n
Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n